Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms.
Cameli, P., Bergantini, L., D'Alessandro, M., Perruzza, M., Cekorja, B., Perillo, F., et al. (2020). A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1-7-7 [10.1159/000507996].
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting
Cameli, Paolo;Bergantini, Laura;d'Alessandro, Miriana;Massa, Evaluna;Ruzza, Annamaria;Beltrami, Valerio;Sestini, Piersante;Bargagli, Elena
2020-01-01
Abstract
Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1111166
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo